Consumer Brands Deal: Tylenol, Kleenex, Band-Aid & More
Here’s a summary of the provided text, focusing on the key points:
* Kenvue‘s Stock Performance: Kenvue, the company behind Tylenol, saw its stock jump over 14% recently, but is still down over 23% for the year.
* Trump & Kennedy’s Claims: The stock surge comes amidst controversy fueled by Donald Trump and Robert F. Kennedy Jr. promoting unsubstantiated claims linking Tylenol (acetaminophen) to autism. Trump even urged pregnant women to avoid the medication.
* FDA & Kenvue’s Response: The FDA advises minimizing acetaminophen use during pregnancy due to inconclusive evidence, but Kenvue strongly refutes any link between the drug and autism, citing sound science. Kennedy has sence reiterated the FDA guidance, stating there’s insufficient evidence to link the drug to autism.
* Investor concerns: Investors are disappointed with Kenvue,citing stalled growth,over-reliance on older brands,and a lack of innovation.
* Industry Trend: Analysts note a poor track record for mergers within the consumer packaged goods industry, pointing to Kraft Heinz’s recent decision to break up its merger as an example.